Semaglutide-induced skin burning
A recent case report described an unusual adverse drug event in a patient with prediabetes.
A case published by Annals of Internal Medicine: Clinical Cases on March 4 discussed an unusual adverse event from a glucagon-like peptide-1 (GLP-1) receptor agonist. An 86-year-old man with prediabetes had skin burning that stopped with withdrawal of semaglutide and recurred when semaglutide was rechallenged a few months later. The patient received multiple other GLP-1 receptor agonists and did not experience this reaction.